DARUNAVIR SANDOZ darunavir 800 mg tablet bottle

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

darunavir, Quantity: 800 mg

Disponibbli minn:

Sandoz Pty Ltd

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

60s

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

Adult patients Darunavir (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adult patients.,Paediatric patients Darunavir (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection in treatment-experienced paediatric patients aged 6 years and older, weighing at least 20 kg.

Sommarju tal-prodott:

Visual Identification: Dark red, oval shaped film-coated tablet, debossed with '800' on one side and plain on the other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2022-04-22